Isis Pharmaceuticals, Merck, Galapagos, Inpharmatica, Invitrogen, Sentigen

Dec 07, 2006

Premium

Isis Receives $1M Milestone From Merck

Isis Pharmaceuticals said this week that it has received a $1 million milestone payment from Merck based on the initiation of clinical development of a compound discovered through a joint research collaboration.

Details about the clinical candidate were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Retirement Moves

The US National Institutes of Health has developed guidelines to gauge whether frail chimpanzees are healthy enough to be moved to a retirement sanctuary.

Osamu Shimomura Dies

Osamu Shimomura, who won the 2008 Nobel Prize in Chemistry for his work on green fluorescent protein, has died.

This Week in PLOS

In PLOS this week: analytical approach for finding new genetic associations, analysis of Streptococcus pyogenes-infecting viruses, and more.

Shuffle at IBM Watson Health

Stat News reports that the head of IBM Watson Health is leaving her post.

Featured White Papers

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Main menu